Highlights of ASCO

Abstract

The Immune-Checkpoint Inhibitor (ICI) therapy that has evolved as a standard of care for stage IV and III is now moving into the early stages. Three studies on ICI-induction therapy in early or locally advanced NSCLC (stages II and III) were presented at ASCO.